Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

James Bradner; Executive Vice President - Research and Development; Amgen Inc Peter Griffith; Executive Vice President and Chief Financial Officer; Amgen Inc Yaron Werber; Analyst; TD Cowen ...

Apellis Pharmaceuticals (APLS – Research Report) received a Hold rating and price target from Goldman Sachs analyst Salveen Richter today. The company’s shares closed yesterday at $33.66.

Op woensdag heeft Goldman Sachs-analist Salveen Richter de rating van het Moderna-aandeel verlaagd van Kopen naar Neutraal, ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. (Operator Instructions) I would now like to ...

mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. The latest guidance reduction was the second time in the last six months that the ...